JP7805946B2 - GABA Aアルファ5受容体調節剤としてのナフチリジンおよびピリド[3,4-c]ピリダジン誘導体 - Google Patents

GABA Aアルファ5受容体調節剤としてのナフチリジンおよびピリド[3,4-c]ピリダジン誘導体

Info

Publication number
JP7805946B2
JP7805946B2 JP2022557102A JP2022557102A JP7805946B2 JP 7805946 B2 JP7805946 B2 JP 7805946B2 JP 2022557102 A JP2022557102 A JP 2022557102A JP 2022557102 A JP2022557102 A JP 2022557102A JP 7805946 B2 JP7805946 B2 JP 7805946B2
Authority
JP
Japan
Prior art keywords
methyl
group
methoxy
tetrahydro
methylpyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022557102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520647A (ja
JP2023520647A5 (enExample
Inventor
ザボー、ジェルジュ
ポトル、アッティラ
バーゴー、イシュトバーン
ジェルジュ、イシュトバーン トゥーローシュ
エーリアーシュ、オリヴィエ
ラースロー カプシュ、ガーボル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of JP2023520647A publication Critical patent/JP2023520647A/ja
Publication of JP2023520647A5 publication Critical patent/JP2023520647A5/ja
Application granted granted Critical
Publication of JP7805946B2 publication Critical patent/JP7805946B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022557102A 2020-03-26 2021-03-25 GABA Aアルファ5受容体調節剤としてのナフチリジンおよびピリド[3,4-c]ピリダジン誘導体 Active JP7805946B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP2000113 2020-03-26
HUP2000113 2020-03-26
PCT/IB2021/052486 WO2021191838A1 (en) 2020-03-26 2021-03-25 NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA α5 RECEPTOR MODULATORS

Publications (3)

Publication Number Publication Date
JP2023520647A JP2023520647A (ja) 2023-05-18
JP2023520647A5 JP2023520647A5 (enExample) 2024-03-11
JP7805946B2 true JP7805946B2 (ja) 2026-01-26

Family

ID=89666363

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022557102A Active JP7805946B2 (ja) 2020-03-26 2021-03-25 GABA Aアルファ5受容体調節剤としてのナフチリジンおよびピリド[3,4-c]ピリダジン誘導体

Country Status (22)

Country Link
US (1) US20240067637A1 (enExample)
EP (1) EP4126859A1 (enExample)
JP (1) JP7805946B2 (enExample)
KR (1) KR20220160061A (enExample)
CN (1) CN115348962A (enExample)
AR (1) AR121666A1 (enExample)
AU (1) AU2021244926A1 (enExample)
BR (1) BR112022019128A2 (enExample)
CA (1) CA3171441A1 (enExample)
CL (1) CL2022002568A1 (enExample)
CO (1) CO2022014877A2 (enExample)
CU (1) CU24714B1 (enExample)
EC (1) ECSP22082367A (enExample)
GE (2) GEAP202416066A (enExample)
IL (1) IL296716A (enExample)
JO (1) JOP20220219A1 (enExample)
MX (1) MX2022011933A (enExample)
PE (1) PE20221836A1 (enExample)
PH (1) PH12022552340A1 (enExample)
TW (1) TWI901650B (enExample)
WO (1) WO2021191838A1 (enExample)
ZA (1) ZA202211414B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231691B1 (hu) * 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009511533A (ja) 2005-10-11 2009-03-19 エフ.ホフマン−ラ ロシュ アーゲー イソオキサゾール誘導体
JP2009514924A (ja) 2005-11-09 2009-04-09 エフ.ホフマン−ラ ロシュ アーゲー 3−アリール−イソオキサゾール−4−カルボニル−ベンゾフラン誘導体
JP2013543852A (ja) 2010-11-09 2013-12-09 エフ.ホフマン−ラ ロシュ アーゲー トリアゾール誘導体及びその神経障害に対する使用
JP2015521642A (ja) 2012-06-26 2015-07-30 サニオナ・エイピイエス フェニルトリアゾール誘導体及びgabaa受受容体複合体を調節するための該フェニルトリアゾール誘導体の使用
WO2018104419A1 (en) 2016-12-08 2018-06-14 F. Hoffmann-La Roche Ag New isoxazolyl ether derivatives as gaba a alpha5 pam

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2728900B1 (fr) * 1994-12-29 1997-01-31 Synthelabo Derives de 3-phenylisoquinolein-1(2h)-one, leur preparation et leur application en therapeutique
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
HU230518B1 (hu) 2005-12-20 2016-10-28 Richter Gedeon Nyrt. Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények
HUP0600808A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0600809A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
HUP0600810A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
AU2012225805B2 (en) * 2011-03-04 2017-03-02 Lexicon Pharmaceuticals, Inc. MST1 kinase inhibitors and methods of their use
DK2937349T3 (en) 2011-03-23 2017-02-20 Amgen Inc CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3
KR20150033679A (ko) 2012-06-26 2015-04-01 사니오나 에이피에스 페닐 트리아졸 유도체 및 이의 gabaa 수용체 복합체 조절용 용도
WO2014001278A1 (en) * 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
CN102924452B (zh) * 2012-11-16 2015-01-21 苏州施亚生物科技有限公司 5,6,7,8-四氢-2H-吡啶并[3,4-c]哒嗪-3-酮的合成方法
HUP1300139A2 (en) 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
CN112409363B (zh) 2013-12-20 2023-11-14 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂䓬衍生物、组合物和方法
US9296747B1 (en) * 2014-10-10 2016-03-29 Allergan, Inc. Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2
KR20180030545A (ko) * 2015-06-22 2018-03-23 다이닛본 스미토모 세이야꾸 가부시끼가이샤 바이사이클릭 헤테로사이클릭 아미드 유도체
JP2018525429A (ja) 2015-08-28 2018-09-06 アッヴィ・インコーポレイテッド S1p調節剤としての縮合複素環化合物
PT3439665T (pt) 2016-03-18 2022-09-27 Uwm Res Foundation Inc Tratamento de sintomas cognitivos e de humor em distúrbios neurodegenerativos e neuropsiquiátricos com gaba contendo agonistas de recetores de gabaa contendo alfa5
WO2018117196A1 (ja) * 2016-12-20 2018-06-28 大日本住友製薬株式会社 がん幹細胞を標的とする医薬
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
HU231058B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt. Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok
ES2902365T3 (es) 2017-11-27 2022-03-28 Dart Neuroscience Llc Compuestos de furanopirimidina sustituidos como inhibidores de PDE1
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素V1a受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
AU2019286312B2 (en) 2018-06-13 2023-08-17 F. Hoffmann-La Roche Ag New isoxazolyl ether derivatives as GABA A alpha5 PAM
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
HU231478B1 (hu) 2018-07-13 2024-02-28 Richter Gedeon Nyrt. Szubsztituált (aza)indol származékok
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
HU231223B1 (hu) * 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009511533A (ja) 2005-10-11 2009-03-19 エフ.ホフマン−ラ ロシュ アーゲー イソオキサゾール誘導体
JP2009514924A (ja) 2005-11-09 2009-04-09 エフ.ホフマン−ラ ロシュ アーゲー 3−アリール−イソオキサゾール−4−カルボニル−ベンゾフラン誘導体
JP2013543852A (ja) 2010-11-09 2013-12-09 エフ.ホフマン−ラ ロシュ アーゲー トリアゾール誘導体及びその神経障害に対する使用
JP2015521642A (ja) 2012-06-26 2015-07-30 サニオナ・エイピイエス フェニルトリアゾール誘導体及びgabaa受受容体複合体を調節するための該フェニルトリアゾール誘導体の使用
WO2018104419A1 (en) 2016-12-08 2018-06-14 F. Hoffmann-La Roche Ag New isoxazolyl ether derivatives as gaba a alpha5 pam

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE STN REGISTRY file, [online], RN 2331259-96-0, Entered STN: 12 Jun 2019, [retrieved on 23 Dec. 2024]
DATABASE STN REGISTRY file, [online], RN 2411227-75-1, Entered STN: 05 Mar 2020, [retrieved on 23 Dec. 2024]
DATABASE STN REGISTRY file,[online], RN 1936066-47-5, Entered STN: 21 Jun 2016, [retrieved on 23 Dec. 2024]
DATABASE STN REGISTRY file,[online], RN 2094374-04-4, Entered STN: 02 May 2017, [retrieved on 23 Dec. 2024]
DATABASE STN REGISTRY file,[online], RN 2094711-87-0, Entered STN: 02 May 2017, [retrieved on 23 Dec. 2024]

Also Published As

Publication number Publication date
BR112022019128A2 (pt) 2022-11-08
TW202202495A (zh) 2022-01-16
PH12022552340A1 (en) 2023-11-29
PE20221836A1 (es) 2022-11-29
AR121666A1 (es) 2022-06-29
US20240067637A1 (en) 2024-02-29
JOP20220219A1 (ar) 2022-09-13
CA3171441A1 (en) 2021-09-30
GEP20257761B (en) 2025-04-10
ZA202211414B (en) 2023-06-28
GEAP202416066A (en) 2024-12-10
KR20220160061A (ko) 2022-12-05
AU2021244926A1 (en) 2022-11-03
CU20220058A7 (es) 2023-05-11
TWI901650B (zh) 2025-10-21
EP4126859A1 (en) 2023-02-08
CO2022014877A2 (es) 2022-10-31
IL296716A (en) 2022-11-01
CN115348962A (zh) 2022-11-15
JP2023520647A (ja) 2023-05-18
ECSP22082367A (es) 2022-11-30
CU24714B1 (es) 2024-07-10
CL2022002568A1 (es) 2023-03-24
WO2021191838A1 (en) 2021-09-30
MX2022011933A (es) 2022-10-20

Similar Documents

Publication Publication Date Title
EA006234B1 (ru) Производные имидазопиримидина в качестве лигандов для гамк рецепторов
EP3856342B1 (en) Bicyclic derivatives as gabaa a5 receptor modulators
JP5117192B2 (ja) 置換ベンゾジアゼピン誘導体
EP4126858B1 (en) Dihydro-2-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators
TWI901650B (zh) 啶及吡啶并〔3,4-c〕嗒衍生物
JP2024536039A (ja) GABAA α5受容体モジュレーターとしての二環式アミン誘導体
WO2015166366A1 (en) Heterocyclic compounds and their use as dopamine d1 ligands
EA049237B1 (ru) ПРОИЗВОДНЫЕ НАФТИРИДИНА И ПИРИДО[3,4-c]ПИРИДАЗИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ АЛЬФА 5 РЕЦЕПТОРОВ GABAA
EA052124B1 (ru) БИЦИКЛИЧЕСКИЕ АМИНОПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ α5 РЕЦЕПТОРОВ GABAA
EA045543B1 (ru) БИЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ КАК МОДУЛЯТОРЫ α5 РЕЦЕПТОРОВ GABAA
EA049500B1 (ru) ПРОИЗВОДНЫЕ 1,3-ДИГИДРО-2Н-ПИРРОЛО[3,4-с]ПИРИДИНА КАК МОДУЛЯТОРЫ α5 РЕЦЕПТОРОВ GABAA

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240229

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240229

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250923

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251223

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260114

R150 Certificate of patent or registration of utility model

Ref document number: 7805946

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150